Abstract:Abstract Patients diagnosed with early stage head and neck squamous cell carcinoma (HNSCC) have a high risk of developing second primary tumors (SPT) or recurrence following curative purpose therapy. To prevent these occurrences, several chemoprevention agents have been developed, including 13-cis-retinoid acid (13-cRA). However, results from clinical trials have remained inconclusive and suggest that biomarkers may be needed to select patients who will receive benefit from therapy. The mTOR signaling pathway plays a major role in the regulation of cell growth, cell survival, and apoptosis. We hypothesized that genetic variation in this pathway may serve as prognostic factors for the development of SPT/recurrence and affect response to chemoprevention therapy. We genotyped 137 SNPs from genes within this pathway in 450 HNSCC patients who received 13-cRA or placebo as part of the Retinoid Head and Neck Second Primary Trial. Genotypes were then analyzed for association with risk of SPT/recurrence to identify biomarkers for prognosis and treatment response. Twenty-two genetic loci were significant prognostic factors for SPT/recurrence in the placebo treatment group. Of these, nine were SNPs within the tuberous sclerosis 1 (TSC1) gene and most often resulted in an increased SPT/recurrence risk for the majority of patients carrying the wild-type genotype. Two of these alleles (rs4962225 and rs7035940) were in strong linkage disequilibrium and resulted in a high risk of SPT/recurrence (HR: 1.92, 95% CI: 1.15–3.23) and a significant 18 month survival disadvantage (Log-rank P = 0.026) in those carrying the wild-type genotype. These results indicate that this locus may be a potential target for chemoprevention. Intriguingly, although 13-cRA did not show a reduction in SPT/recurrence risk overall, response to this therapy was significantly different depending on the patient's genetic background for these potential targets. A significant modulation of SPT/recurrence risk in those who received 13-cRA was observed for seven of the prognostic TSC1 SNPs. The majority of the population with the wild-type genotype were conferred the protective effect of 13-cRA, indicating that the high-risk group for SPT/recurrence were being effectively treated by this chemoprevention intervention. Individuals carrying the wild-type genotype for either TSC1 rs4962225 or rs7035940 were at a 43% reduced risk (95% CI: 0.37–0.88). However those who carried at least one variant allele did not receive the benefit of 13-cRA treatment and were at an increased risk (HR: 1.91, 95% CI: 1.10–3.32). These results indicate that genetic variation within the mTOR pathway, particularly TSC1, could potentially be used to better identify patients who are at high-risk of SPT/recurrence and also those who are candidates for chemoprevention therapy based on their favorable genetic background. Citation Information: Cancer Prev Res 2010;3(1 Suppl):B94.

Novel Susceptibility Loci for Second Primary Tumors/Recurrence in Head and Neck Cancer Patients: Large-Scale Evaluation of Genetic Variants

Genetic Variants in the Telomere Maintenance Pathway As Predictors of Second Primary Tumors and Recurrence of Early-Stage Head and Neck Cancer

Genetic variations in regulator of G-protein signaling genes as susceptibility loci for second primary tumor/recurrence in head and neck squamous cell carcinoma.

MicroRNA-related genetic variations as predictors for risk of second primary tumor and/or recurrence in patients with early-stage head and neck cancer.

Predictive Biomarkers and Personalized Medicine Genetic Variants in the PI 3 K / PTEN / AKT / mTOR Pathway Predict Head and Neck Cancer Patient Second Primary Tumor / Recurrence Risk and Response to Retinoid Chemoprevention

Abstract PR-03: Genetic Variations in Microrna Biogenesis Genes As Predictors for Risk of Second Primary Tumor (SPT) And/or Recurrence in Patients with Early-Stage Head and Neck Cancer

A Genome-Wide Association Study Identifies Two Novel Susceptible Regions for Squamous Cell Carcinoma of the Head and Neck.

Global Assessment of Genetic Variation Influencing Response to Retinoid Chemoprevention in Head and Neck Cancer Patients

Abstract B94: Pharmacogenetics of Retinoid Chemoprevention in Head and Neck Cancer Patients: Modulation of Response by Common Genetic Variation in the Mtor Signaling Pathway

Predictive Biomarkers and Personalized Medicine Genetic Variations in Epigenetic Genes Are Predictors of Recurrence in Stage I or II Non – Small Cell Lung Cancer Patients

Genetic Variations in Epigenetic Genes Are Predictors of Recurrence in Stage I or Ii Non-Small Cell Lung Cancer Patients

Cross-ancestral GWAS identifies 29 novel variants across Head and Neck Cancer subsites

Genetic variants of the Wnt signaling pathway as predictors of recurrence and survival in early-stage non-small cell lung cancer patients.

Identification of novel prognosticators of outcome in squamous cell carcinoma of the head and neck

Telomere Length-Associated Genetic Variants Predict Recurrence Risk in Non-Oropharyngeal Squamous Cell Carcinoma Patients

Joint Effect of Mutagen Sensitivity and Insulin-Like Growth Factors in Predicting the Risk of Developing Secondary Primary Tumors and Tumor Recurrence in Patients with Head and Neck Cancer

GSTM1 Copy Number and Promoter Haplotype As Predictors for Risk of Recurrence And/or Second Primary Tumor in Patients with Head and Neck Cancer

Genetic Variants Associated with Expression of TCF19 Contribute to the Risk of Head and Neck Cancer in Chinese Population.

Identification and Validation of a Novel Tumor Driver Gene Signature for Diagnosis and Prognosis of Head and Neck Squamous Cell Carcinoma

Tumor Genomics and the Association with Survival in Recurrent/metastatic Head and Neck Cancer Patients

Genetic Biomarkers in Head and Neck Squamous Cell Carcinoma